Tandem Diabetes Care (MEX:TNDM) Cyclically Adjusted Revenue per Share: MXN592.66 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:TNDM Tandem Diabetes Care Inc MEX:TNDM
66 GF Score
Price MXN745.00
GF Value MXN1,304.19
! 5 Warning Signs
View Full Analysis

What is Tandem Diabetes Care Cyclically Adjusted Revenue per Share?

Tandem Diabetes Care MEX:TNDM 66 Cyclically Adjusted Revenue per Share is MXN592.66 as of Mar. 2026. GuruFocus rates MEX:TNDM with a GF Score™ of 66/100 and a GF Value™ of MXN1,304.19. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Tandem Diabetes Care's adjusted revenue per share for the three months ended in Mar. 2026 was MXN65.179. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN592.66 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Tandem Diabetes Care's average Cyclically Adjusted Revenue Growth Rate was -9.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Tandem Diabetes Care was -5.30% per year. The lowest was -5.30% per year. And the median was -5.30% per year.

As of today (2026-07-26), Tandem Diabetes Care's current stock price is MXN745.00. Tandem Diabetes Care's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN592.66. Tandem Diabetes Care's Cyclically Adjusted PS Ratio of today is 1.26.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Tandem Diabetes Care was 6.99. The lowest was 0.65. And the median was 1.63.


Tandem Diabetes Care  (MEX:TNDM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Tandem Diabetes Care's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=745.00/592.66
=1.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Tandem Diabetes Care was 6.99. The lowest was 0.65. And the median was 1.63.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Tandem Diabetes Care Cyclically Adjusted Revenue per Share Related Terms


Tandem Diabetes Care Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Tandem Diabetes Care's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tandem Diabetes Care Cyclically Adjusted Revenue per Share Chart

Tandem Diabetes Care Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 328.44 486.82 349.21 525.70

Tandem Diabetes Care Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 656.35 666.66 1,009.49 525.70 592.66

MEX:TNDM vs CNMD, AORT, LMRI: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Tandem Diabetes Care's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tandem Diabetes Care Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Tandem Diabetes Care's Cyclically Adjusted PS Ratio falls into.


MEX:TNDM
66GF Score
Tandem Diabetes Care Inc MEX:TNDM
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tandem Diabetes Care Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Tandem Diabetes Care's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=65.179/330.2130*330.2130
=65.179

Current CPI (Mar. 2026) = 330.2130.

Tandem Diabetes Care Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 139.414 241.018 191.008
201609 77.601 241.428 106.139
201612 193.093 241.432 264.098
201703 112.047 243.801 151.761
201706 77.040 244.955 103.854
201709 94.422 246.819 126.325
201712 78.207 246.524 104.756
201803 27.542 249.554 36.444
201806 13.162 251.989 17.248
201809 15.560 252.439 20.354
201812 26.004 251.233 34.179
201903 22.159 254.202 28.785
201906 30.769 256.143 39.667
201909 31.568 256.759 40.599
201912 34.520 256.974 44.358
202003 38.436 258.115 49.172
202006 41.728 257.797 53.450
202009 44.378 260.280 56.302
202012 53.700 260.474 68.078
202103 46.165 264.877 57.552
202106 52.185 271.696 63.424
202109 57.012 274.310 68.631
202112 66.477 278.802 78.735
202203 54.829 287.504 62.974
202206 62.874 296.311 70.068
202209 64.051 296.808 71.260
202212 66.767 296.797 74.284
202303 47.299 301.836 51.746
202306 51.809 305.109 56.072
202309 49.654 307.789 53.272
202312 51.098 306.746 55.007
202403 48.695 312.332 51.483
202406 62.551 314.175 65.744
202409 73.299 315.301 76.766
202412 89.393 315.605 93.531
202503 72.222 319.799 74.574
202506 67.588 322.561 69.191
202509 67.586 324.800 68.712
202512 76.868 324.054 78.329
202603 65.179 330.213 65.179

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN592.66 mean?
Tandem Diabetes Care (MEX:TNDM) has a Cyclically Adjusted Revenue per Share of MXN592.66 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Tandem Diabetes Care and its competitors.
Is Tandem Diabetes Care's Cyclically Adjusted Revenue per Share too high?
Tandem Diabetes Care's current Cyclically Adjusted Revenue per Share is MXN592.66. Overall, Tandem Diabetes Care has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Cyclically Adjusted Revenue per Share compare to CNMD and AORT?
Tandem Diabetes Care's Cyclically Adjusted Revenue per Share of MXN592.66 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Tandem Diabetes Care and its competitors. Tandem Diabetes Care's current Cyclically Adjusted Revenue per Share is MXN592.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Tandem Diabetes Care (MEX:TNDM) has a current Cyclically Adjusted Revenue per Share of MXN592.66. The stock's GF Value™ is MXN1,304.19, compared to a current price of MXN745.00 — trading 42.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN592.66. Tandem Diabetes Care's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Tandem Diabetes Care (MEX:TNDM), the current Cyclically Adjusted Revenue per Share is MXN592.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tandem Diabetes Care (MEX:TNDM) Overvalued in 2026?

Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued. The current stock price of MXN745.00 is trading 42.9% below its estimated GF Value™ of MXN1,304.19.

Key valuation signals for MEX:TNDM:

  • Cyclically Adjusted Revenue per Share: MXN592.66
  • GF Value™: MXN1,304.19 vs. price of MXN745.00 (42.9% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the MEX:TNDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tandem Diabetes Care Business Description

Address 12400 High Bluff Drive, San Diego, CA, USA, 92130
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
66GF Score

Get the complete analysis for MEX:TNDM

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN745.00
Price
MXN1,304.19
GF Value